510(k) device
Intimate Rose Pelvic Wand (Purple)
Plus EV Holdings, Inc. D/B/A Intimate Rose · Massager, Therapeutic, To Internally Massage Trigger Points In The Pelvic Floor Musculature (OSD, Class II) · First FDA decision Jul 27, 2026, newest Jul 27, 2026Endometriosis and pelvic pain
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Intimate Rose"
MAUDE reports
1
Brand "Intimate Rose", since 2015
PubMed studies
0
Mentioning "Intimate Rose"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Intimate Rose Pelvic Wand (Purple)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K250419 · Decided Jul 27, 2026 · 529 days after receipt
Device type: Massager, Therapeutic, To Internally Massage Trigger Points In The Pelvic Floor Musculature (OSD) · Physical Medicine & Rehabilitation
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Pelvic Floor Electrical Stimulation for Urinary IncontinenceNational analysisReview closedCAG-00021NUpdated Sep 15, 2026
- Non-Implantable Pelvic Floor Electrical StimulatorNational determinationOn the books230.8Updated Aug 17, 2023
- Trigger Point InjectionsLocal determinationIn effectL33912First Coast Service Options, Inc.Updated Oct 2, 2026
- Trigger Point InjectionsLocal determinationIn effectL35010Novitas Solutions, Inc.Updated Jul 17, 2026
- Trigger Point Injections (TPI)Local determinationIn effectL39662Wellpoint FederalUpdated Jul 14, 2026
- Trigger Point InjectionsProposed local determinationProposedDL33912First Coast Service Options, Inc.Updated Feb 13, 2026
- Trigger Point InjectionsProposed local determinationProposedDL35010Novitas Solutions, Inc.Updated Feb 13, 2026
- Trigger Point InjectionsLocal determinationIn effectL39713WPS Insurance CorporationUpdated Jan 22, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Intimate Rose", any status and sponsor, newest update first.
No registered device study names "Intimate Rose".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Intimate Rose", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 0 injury, 0 death
Whole product code OSD
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
SHENZHEN ENOVART TECHNOLOGY CO., LTD
MW5116435 · Received Apr 6, 2023
Device type: Dilator, Vaginal (HDX)
Device problem as coded: Use of Device Problem; Device Markings/Labelling Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Intimate Rose"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code OSD.
- Ahip Internal Trigger Point Wand Model: 1National Center For Pelvic Pain Research Devices · De Novo 2012
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.